First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking...
Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for...
Most competitive selection process so far since the launch of the Accelerator under Horizon Europe Follow-on funding reflects significant potential...
Leiden, The Netherlands, 10 December 2024 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral...
Oral and poster presentations on key VMX-001 data in San Diego from 7-10 December Leiden, The Netherlands, 3 December 2024...
Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...
Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...
Leiden, The Netherlands, 26 June 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...